Comparative Pharmacology
Head-to-head clinical analysis: FOMEPIZOLE versus METHYLENE BLUE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FOMEPIZOLE versus METHYLENE BLUE.
FOMEPIZOLE vs METHYLENE BLUE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fomepizole is a competitive inhibitor of alcohol dehydrogenase, the enzyme that catalyzes the first step in the metabolism of ethylene glycol and methanol to their toxic metabolites. By inhibiting alcohol dehydrogenase, fomepizole prevents the formation of toxic metabolites such as glycolic acid, glyoxylic acid, and oxalic acid from ethylene glycol, and formic acid from methanol.
Methylene blue is a dye that acts as a redox agent, reducing methemoglobin to hemoglobin by activating the enzyme methemoglobin reductase. It also inhibits nitric oxide synthase and guanylate cyclase, causing vasoconstriction in septic shock.
Loading dose of 15 mg/kg intravenously over 15 minutes, followed by 10 mg/kg every 12 hours for 4 doses, then 15 mg/kg every 12 hours if ethanol co-ingestion is present; otherwise 10 mg/kg every 12 hours until ethylene glycol or methanol levels <20 mg/dL.
1-2 mg/kg IV over 5-30 minutes for methemoglobinemia; repeat after 1 hour if needed. Maximum dose: 7 mg/kg.
None Documented
None Documented
Clinical Note
moderateMethylene blue + Torasemide
"Methylene blue may increase the hypotensive activities of Torasemide."
Clinical Note
moderateMethylene blue + Travoprost
"Methylene blue may increase the hypotensive activities of Travoprost."
Clinical Note
moderateMethylene blue + Unoprostone
"Methylene blue may increase the hypotensive activities of Unoprostone."
Clinical Note
moderateMethylene blue + Hydrochlorothiazide
Terminal: 5-7 hours in healthy adults; prolonged to 8-14 hours in patients with ethanol co-ingestion due to competitive inhibition; no significant change in severe renal impairment.
Terminal elimination half-life approximately 12–24 hours; clinically, levels may persist for 2–3 days due to enterohepatic recycling
Renal: 70-90% as unchanged drug and metabolites (4-carboxypyrazole, 4-hydroxymethylpyrazole); biliary/fecal: minor (<5% total).
Renal (80% as leukomethylene blue and unchanged drug); biliary/fecal minor
Category C
Category C
Antidote
Antidote
"Methylene blue may increase the hypotensive activities of Hydrochlorothiazide."